Entrada Therapeutics, Inc. (TRDA)


-0.13 (-0.86%)
Symbol TRDA
Price $14.95
Beta 0.000
Volume Avg. 0.05M
Market Cap 494.492M
Shares () -
52 Week Range 5.12-24.38
1y Target Est -
DCF Unlevered TRDA DCF ->
DCF Levered TRDA LDCF ->
ROE -38.65% Strong Sell
ROA -37.54% Strong Sell
Operating Margin -
Debt / Equity 18.58% Neutral
P/E -5.12 Strong Sell
P/B 2.20 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest TRDA news

Mr. Dipal Doshi
NASDAQ Global Market

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.